Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28575636 | 0.83 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2KDM4EHTTMEN1 | |
| SCHEMBL3587984 | 0.81 | KDM4E (0.48) | ALDH1A1GAASMN1; SMN2MAPTHSP90AB1 | |
| SCHEMBL1592992 | 0.78 | GABRA5 (0.43) | ALDH1A1MAPTKDM4EHSD17B10MEN1 | |
| SCHEMBL20455653 | 0.78 | HCAR3 (0.45) | ALDH1A1SMN1; SMN2MAPTHSP90AB1KDM4E | |
| SCHEMBL3454155 | 0.72 | ALDH1A1 (0.41) | ALDH1A1GAAGFERSMN1; SMN2MAPT | |
| SCHEMBL14688686 | 0.72 | LMNA (0.41) | ALDH1A1GAASMN1; SMN2KDM4EHTT | |
| SCHEMBL5069229 | 0.72 | — | — | |
| SCHEMBL1201703 | 0.70 | KDM4E (0.41) | ALDH1A1GAAGFERSMN1; SMN2MAPT | |
| SCHEMBL1009738 | 0.69 | MAPK1 (0.65) | GAAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL4109248 | 0.69 | SMN1; SMN2 (0.44) | ALDH1A1GAAGFERSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899345-B1 | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-16 | — | — | EP | disclosed |
| CN-101074227-B | Phosphine acyloxy quinazoline derivatives and their medicine uses | ASTRAZENECA AB | 2010-09-29 | — | — | CN | disclosed |
| CN-100491372-C | Substituted quinazoline derivatives as inhibitors of aurora kinase | ASTRAZENECA AB (SE) | 2009-05-27 | — | — | CN | disclosed |
| US-7402582-B2 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1899345-A1 | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-03-19 | — | — | EP | disclosed |
| CN-101074227-A | Phosphine acyloxy quinazoline derivatives and their medicine using | ASTRAZENECA AB (SE) | 2007-11-21 | — | — | CN | disclosed |
| CN-100349906-C | Phosphonoxyquinazoline derivatives and pharmaceutical use thereof | ASTRAZENECA AB (SE) | 2007-11-21 | — | — | CN | disclosed |
| WO-2007005630-A1 | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004732-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| CN-1764668-A | Phosphonoxyquinazoline derivatives and pharmaceutical use thereof | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | CN | disclosed |
| CN-1620296-A | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004732-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | MAP3K20, PRKDC, MAP3K2 | ALDH1A1 4028/4885GAA 1518/4885GFER 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.